Responses
Clinical/translational cancer immunotherapy
Original research
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
Compose a Response to This Article
Other responses
No responses have been published for this article.